p53 polymorphisms: cancer implications - PubMed (original) (raw)

Review

doi: 10.1038/nrc2584.

Affiliations

Review

p53 polymorphisms: cancer implications

Catherine Whibley et al. Nat Rev Cancer. 2009 Feb.

Abstract

The normal functioning of p53 is a potent barrier to cancer. Tumour-associated mutations in TP53, typically single nucleotide substitutions in the coding sequence, are a hallmark of most human cancers and cause dramatic defects in p53 function. By contrast, only a small fraction, if any, of the >200 naturally occurring sequence variations (single nucleotide polymorphisms, SNPs) of TP53 in human populations are expected to cause measurable perturbation of p53 function. Polymorphisms in the TP53 locus that might have cancer-related phenotypical manifestations are the subject of this Review. Polymorphic variants of other genes in the p53 pathway, such as MDM2, which might have biological consequences either individually or in combination with p53 variants are also discussed.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Natl Cancer Inst. 2006 Jul 5;98(13):911-9 - PubMed
    1. Cancer Res. 2007 Mar 15;67(6):2757-65 - PubMed
    1. Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15335-40 - PubMed
    1. Breast Cancer Res Treat. 2006 Jun;97(3):255-62 - PubMed
    1. Cancer Lett. 2002 Sep 26;183(2):123-30 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources